Jim Hoffman: Could Extracorporeal Removal of NETs Become a ‘Holy Grail’ Therapy Across Multiple Diseases?
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared a post on LinkedIn about a recent article by Michal Santocki and Elzbieta Kolaczkowska, published in Cells:
“Could extracorporeal removal of NETs and other extracellular chromatin outperform many drug treatments with the potential to be a holy grail treatment for multiple diseases and disorders, slowing their progression and aiding recovery, largely free of systemically administered drug-related side effects?
Recent evidence, courtesy of Santersus AG, treating severe Lupus, and backed by over two decades of NETosis research, suggests we should pay much more attention to the universal potential of this therapy to transform disease management, since dysregulated NETosis contributes to the progression of most, if not all, diseases.”
Title: On Neutrophil Extracellular Trap (NET) Removal: What We Know Thus Far and Why So Little
Authors: Michal Santocki, Elzbieta Kolaczkowska
Read the Full Article on Cells.
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 20, 2026, 10:40Omid Seidizadeh: Advancing Genomic Insights into Bleeding Disorders at ISTH 2026
-
Jul 20, 2026, 10:30Marc Blondon: What Are the Current Practices For VTE Prevention in Pregnancy Worldwide?
-
Jul 20, 2026, 10:11Zeyad Bady: Advancing Thrombosis Research on the International Stage at ISTH 2026
-
Jul 20, 2026, 09:41Emily Bury: From Emerging Evidence to Better Patient Care at ISTH 2026
-
Jul 20, 2026, 08:58Samantha Pasca: Insights into Pain and Coping in Hemophilia at ISTH 2026
-
Jul 20, 2026, 08:08Ifeanyichukwu Ifechidere: COVID-19 Changed Our Understanding of Coagulation
-
Jul 20, 2026, 07:27Vonwicks Czelestakov Onyango: The Anticoagulation Dilemma in Ulcerative Colitis
-
Jul 20, 2026, 06:14Elen Avetisyan: A Memorable Week of Science and Collaboration at ISTH 2026
-
Jul 19, 2026, 16:59Rupam Manna: Not All Portal Vein Involvement in HCC Is the Same